about
Electron Transport Disturbances and Neurodegeneration: From Albert Szent-Györgyi's Concept (Szeged) till Novel Approaches to Boost Mitochondrial BioenergeticsKynurenines in the CNS: recent advances and new questions.Mitochondrial disturbances, tryptophan metabolites and neurodegeneration: medicinal chemistry aspects.Manipulating kynurenic acid levels in the brain - on the edge between neuroprotection and cognitive dysfunction.Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson's disease.Glutamatergic dysfunctioning in Alzheimer's disease and related therapeutic targets.Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease.The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis.Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).High-dose 1,25-dihydroxyvitamin D supplementation elongates the lifespan of Huntington's disease transgenic mice.Lack of age-related clinical progression in PGC-1α-deficient mice - implications for mitochondrial encephalopathies.Association of vitamin D receptor gene polymorphisms and Parkinson's disease in Hungarians.Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice.mRNA expression levels of PGC-1α in a transgenic and a toxin model of Huntington's disease.Central nervous system-specific alterations in the tryptophan metabolism in the 3-nitropropionic acid model of Huntington's disease.Neuropathology of partial PGC-1α deficiency recapitulates features of mitochondrial encephalopathies but not of neurodegenerative diseases.Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity.Unlike PPARgamma, neither other PPARs nor PGC-1alpha is elevated in the cerebrospinal fluid of patients with multiple sclerosis.PACAP and its role in primary headaches.Alzheimer's Disease: Recent Concepts on the Relation of Mitochondrial Disturbances, Excitotoxicity, Neuroinflammation, and Kynurenines.B7 costimulation and intracellular indoleamine 2,3-dioxygenase expression in umbilical cord blood and adult peripheral bloodNon-motor Behavioral Alterations of PGC-1α-Deficient Mice - A Peculiar Phenotype With Slight Male Preponderance and No Apparent ProgressionDrug-induced movement disordersElevated levels of PPAR-gamma in the cerebrospinal fluid of patients with multiple sclerosisExploiting the Therapeutic Potential of Endogenous Immunomodulatory Systems in Multiple Sclerosis-Special Focus on the Peroxisome Proliferator-Activated Receptors (PPARs) and the KynureninesPredictors of localization, outcome, and etiology of spontaneous intracerebral hemorrhages: focus on cerebral amyloid angiopathyAdditional value of tau protein measurement in the diagnosis of Creutzfeldt-Jakob diseaseCorrection to: Predictors of localization, outcome, and etiology of spontaneous intracerebral hemorrhages: focus on cerebral amyloid angiopathy
P50
Q26795417-62378DD5-D2BE-4314-97FA-DCF76D823511Q34317484-913FB761-32DC-4A50-90A1-60F52B4E7D53Q37994780-0E67730D-6B10-45CA-A081-69DFEC4CA4AFQ38048907-D001E65F-1D69-4FBD-881F-ACE2DE38D523Q38063779-68B2C820-9FBE-4F04-A4BC-69C4EDD198B1Q38199559-D4CF4E2C-F8C7-4152-B5F5-4B2A4BCF0058Q38817063-33E0B6F3-A5C4-4263-95BD-A5D90D3E8F3CQ38830945-0DB316DF-B5F0-49F3-B5AD-69362BA8442CQ38832886-371722E0-79DD-4E1C-A407-08FEC3811521Q39338803-723A75F6-4EB5-46FC-8AA0-CCE4E00F1F25Q39594110-1B2C1983-0E69-4704-B758-AD2024039E54Q44722260-E76322A8-D433-4AE7-B8C7-9BBFB14B72EFQ44940075-ECBD0EBB-E1D4-4F83-99A7-35383663DCC0Q45302304-AAB8346D-C759-40FC-9673-CFF38FF5365CQ45304792-2826FE6D-37A6-47B1-BF18-C908B68CAD40Q46842418-1F687B8B-EC72-4F54-8AF6-0B67C23A2704Q50962057-6170D9C7-2066-476D-874A-412118A96B00Q51014236-8A195792-19C8-4772-BCF9-F1D970410AA5Q52360955-DA6956C8-7799-47BC-9932-B1921BEF7801Q52685697-E95B00B8-6A9E-46C4-BEE7-571EF00C7CECQ56896627-07ED4B9F-45E2-4CE1-8D47-6E1B2CDC8F86Q58700726-E641DC9B-9061-45BC-91A3-88ED1BF0E72DQ60732882-608C26B3-1D2C-4B40-B41E-8C38A2593DF3Q60732901-C9CC3B8F-2F7F-4C0B-AA61-505FB42BE243Q61812962-F4A5F47B-5F57-4656-B583-255B746B750EQ90473464-CCBA6889-B6C4-4B0F-AC8A-A6363C2F7185Q91742460-11BC5EBE-EF9B-44FE-8F06-A307C0CBEDA0Q94597516-84D728D5-0BDF-4F45-899A-661E1495F39A
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
L Szalardy
@en
L Szalardy
@nl
type
label
L Szalardy
@en
L Szalardy
@nl
prefLabel
L Szalardy
@en
L Szalardy
@nl
P31
P496
0000-0002-1084-6195